Browse YY1

Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus matrix Note=Associated with the nuclear matrix.
Domain -
Function

Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes by binding to sites overlapping the transcription start site. Binds to the consensus sequence 5'-CCGCCATNTT-3'; some genes have been shown to contain a longer binding motif allowing enhanced binding; the initial CG dinucleotide can be methylated greatly reducing the binding affinity. The effect on transcription regulation is depending upon the context in which it binds and diverse mechanisms of action include direct activation or repression, indirect activation or repression via cofactor recruitment, or activation or repression by disruption of binding sites or conformational DNA changes. Its activity is regulated by transcription factors and cytoplasmic proteins that have been shown to abrogate or completely inhibit YY1-mediated activation or repression. For example, it acts as a repressor in absence of adenovirus E1A protein but as an activator in its presence. Acts synergistically with the SMAD1 and SMAD4 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (PubMed:15329343). Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions. May play an important role in development and differentiation. Proposed to recruit the PRC2/EED-EZH2 complex to target genes that are transcriptional repressed. Involved in DNA repair. In vitro, binds to DNA recombination intermediate structures (Holliday junctions). Plays a role in regulating enhancer activation (PubMed:28575647). ; FUNCTION: Proposed core component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair; proposed to target the INO80 complex to YY1-responsive elements.

> Gene Ontology
 
Biological Process GO:0000724 double-strand break repair via homologous recombination
GO:0000725 recombinational repair
GO:0001654 eye development
GO:0003002 regionalization
GO:0006302 double-strand break repair
GO:0006310 DNA recombination
GO:0006403 RNA localization
GO:0007283 spermatogenesis
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009952 anterior/posterior pattern specification
GO:0010225 response to UV-C
GO:0034644 cellular response to UV
GO:0034694 response to prostaglandin
GO:0034696 response to prostaglandin F
GO:0043010 camera-type eye development
GO:0048232 male gamete generation
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0070555 response to interleukin-1
GO:0071214 cellular response to abiotic stimulus
GO:0071347 cellular response to interleukin-1
GO:0071478 cellular response to radiation
GO:0071482 cellular response to light stimulus
GO:0090596 sensory organ morphogenesis
Molecular Function GO:0000217 DNA secondary structure binding
GO:0000400 four-way junction DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003713 transcription coactivator activity
GO:0003714 transcription corepressor activity
GO:0035326 enhancer binding
GO:0042826 histone deacetylase binding
GO:0043566 structure-specific DNA binding
GO:0046332 SMAD binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005667 transcription factor complex
GO:0016363 nuclear matrix
GO:0031011 Ino80 complex
GO:0031519 PcG protein complex
GO:0033202 DNA helicase complex
GO:0034399 nuclear periphery
GO:0044454 nuclear chromosome part
GO:0070603 SWI/SNF superfamily-type complex
GO:0097346 INO80-type complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-5696394: DNA Damage Recognition in GG-NER
R-HSA-73894: DNA Repair
R-HSA-5688426: Deubiquitination
R-HSA-1266738: Developmental Biology
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-392499: Metabolism of proteins
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-597592: Post-translational protein modification
R-HSA-8866910: TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-5689603: UCH proteinases
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between YY1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of YY1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of YY1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1580.393
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3930.846
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0160.991
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2580.406
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6140.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1920.95
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0120.977
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0460.979
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0750.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2720.844
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8550.68
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.080.149
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of YY1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of YY1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of YY1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by YY1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of YY1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of YY1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between YY1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolYY1
NameYY1 transcription factor
Aliases UCRBP; YIN-YANG-1; INO80S; INO80 complex subunit S; Yin and Yang 1 protein; YY-1; delta transcription factor ......
Chromosomal Location14q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting YY1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.